inactivated whole-cell pneumococcal vaccine (Gamma-PN3) / Gamma Vaccines - LARVOL DELTA

Extension Safety and Immunogenicity Study of GPNV-001 (clinicaltrials.gov) - P1/2 | N=60 | Completed | Sponsor: GPN Vaccines | Recruiting ➔ Completed

Trial completion • Infectious Disease • Pneumococcal Infections

Study of Gamma PN3 in the Elderly (clinicaltrials.gov) - P1 | N=105 | Recruiting | Sponsor: GPN Vaccines | Not yet recruiting ➔ Recruiting

Enrollment open • Pneumococcal vaccines • Infectious Disease • Pneumococcal Infections • Pneumonia • Respiratory Diseases

Safety, Tolerability and Immunogenicity of an Inactivated Whole-cell Pneumococcal Vaccine Gamma-PN3. (clinicaltrials.gov) - P1 | N=118 | Completed | Sponsor: GPN Vaccines | Recruiting ➔ Completed

Pneumococcal vaccines • Trial completion • Infectious Disease • Pneumococcal Infections

Study of Gamma PN3 in the Elderly (clinicaltrials.gov) - P1 | N=105 | Not yet recruiting | Sponsor: GPN Vaccines

New P1 trial • Pneumococcal vaccines • Infectious Disease • Pneumococcal Infections • Pneumonia • Respiratory Diseases

FIRST-IN-HUMAN TRIAL OF A WHOLE CELL VACCINE THAT ELICITS POTENT SEROTYPE-INDEPENDENT OPSONOPHAGOCYTIC ANTIBODY RESPONSES (ISPPD 2024) - "A further nine participants per cohort were injected with either an approved dose of Prevnar 13® (n=3), Pneumovax 23® (n=3) or placebo on Day 1, and all injected with placebo on Day 29. Gamma-PN3 is a novel WCV undergoing a Phase 1 trial to assess its acute safety, tolerability, and immunogenicity. Preliminary data show Gamma-PN3 is safe and well-tolerated. Immunological testing is underway."

P1 data • Infectious Disease • Pneumococcal Infections • Pneumonia

Extension Safety and Immunogenicity Study of GPNV-001 (clinicaltrials.gov) - P1/2 | N=60 | Recruiting | Sponsor: GPN Vaccines

New P1/2 trial • Infectious Disease • Pneumococcal Infections

Safety, Tolerability and Immunogenicity of an Inactivated Whole-cell Pneumococcal Vaccine Gamma-PN3. (clinicaltrials.gov) - P1 | N=117 | Recruiting | Sponsor: GPN Vaccines

New P1 trial • Pneumococcal vaccines • Infectious Disease • Pneumococcal Infections